Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03270176
Title A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Debiopharm International SA
Indications

Advanced Solid Tumor

lung non-small cell carcinoma

Therapies

Avelumab + Xevinapant

Age Groups: senior | adult
Covered Countries CAN

Facility Status City State Zip Country Details
Cross Cancer Center Dept Medicine Edmonton Alberta T6G 1Z2 Canada Details
British Columbia Cancer Agency Vancouver British Columbia V5Z 4E6 Canada Details
Juravinski Cancer Centre Hamilton Ontario L8V 5C2 Canada Details
The Ottawa Hospital Cancer Centre (TOHCC) Ottawa Ontario K1H 8L6 Canada Details
Med-Polonia Sp. z o.o., Ulica Obornicka Poznań 60-693 Poland Details
Wojewódzki Szpital Zespolony im. Ludwika Rydygiera Toruń 87-100 Poland Details
Instytut Medyczny Santa Familia Sp. z o. o. Łódź 90-320 Poland Details
Institutul Oncologic "Prof. Dr. Ion Chiricuţă" Cluj Napoca Cluj-Napoca 400015 Romania Details
Centrul de Oncologie, S.C. Centrul de Oncologie Sf. Nectarie S.R.L, Oncologie Medicala Craiova 200347 Romania Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field